Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foretinib plus Erlotinib in Previously Treated NSCLC
NCT01068587Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jan 2010
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of foretinib in non-small cell lung cancer (NSCLC), sponsored by Canadian Cancer Trials Group. Started Jan 2010; status: completed.
02
Drugs
foretinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01068587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01068587.